{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:51Z","timestamp":1790313531073,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":1450,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030825","name":"Ascendis Pharma A\/S","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100030825","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ascendis Pharma A\/S","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>TransCon PTH is a sustained-release, essentially inactive prodrug transiently bound to an inert carrier, designed to release PTH(1-34), and in development for hypoparathyroidism (HP). This phase 1, randomized, placebo-controlled, single and multiple ascending dose (SAD and MAD, respectively) trial evaluated safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of TransCon PTH in healthy adults. SAD and MAD cohorts consisted of 10 subjects (eight active, two placebo) who received up to seven single or six multiple ascending doses of TransCon PTH, respectively. TransCon PTH doses ranged from 3.5 to 124 \u03bcg PTH(1-34) for the SAD cohorts and 3.5 to 24 \u03bcg PTH(1-34)\/day for the MAD cohorts. The primary PK endpoint was Free PTH. The PD endpoints included albumin adjusted serum calcium (sCa), fractional excretion of calcium (FECa), intact endogenous PTH(1-84), bone turnover markers, renal tubular maximum reabsorption of phosphate\/glomerular filtration rate (TMP\/GFR), serum phosphate (sP) and magnesium, and 1,25 dihydroxyvitamin D. TransCon PTH was generally well tolerated; there were no drug-related serious adverse events (SAEs), and all AEs were transient in nature. Free PTH demonstrated an effective half-life of approximately 60 hours and a dose-dependent, sustained exposure with an infusion-like profile within the calculated physiologic range for active PTH at steady-state. Albumin-adjusted sCa demonstrated a dose-dependent, sustained response with complete control of FECa despite modest hypercalcemia at higher doses. Renal tubular maximum reabsorption of phosphate\/glomerular filtration rate (TMP\/GFR) showed a dose-dependent decrease, resulting in a dose-dependent decrease in sP. TransCon PTH administered daily for 10\u2009days showed no increase in the osteoblastic bone formation markers, serum bone-specific alkaline phosphatase (BSAP) or P1NP, or the osteoclastic bone resorption marker, urine NTx, but modestly and transiently increased the osteoclast marker, serum CTx. These phase 1 data support TransCon PTH as a daily replacement therapy for HP providing physiological levels of PTH 24 hours per day and advancement into phase 2 clinical development. \u00a9 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.4016","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T07:35:40Z","timestamp":1585121740000},"page":"1430-1440","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults"],"prefix":"10.1093","volume":"35","author":[{"given":"David B","family":"Karpf","sequence":"first","affiliation":[{"name":"Ascendis Pharma, Inc. Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Pihl","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchita","family":"Mourya","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc. Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-5164","authenticated-orcid":false,"given":"Eva","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc. Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshwari","family":"Kovoor","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc. Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denka","family":"Markova","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc. Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A","family":"Leff","sequence":"additional","affiliation":[{"name":"Ascendis Pharma, Inc. Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"issue":"4","key":"2024031418592933600_jbmr4016-bib-0001","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S8756-3282(00)00355-0","article-title":"Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice","volume":"27","author":"Mohan","year":"2000","journal-title":"Bone"},{"issue":"6","key":"2024031418592933600_jbmr4016-bib-0002","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024031418592933600_jbmr4016-bib-0003","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024031418592933600_jbmr4016-bib-0004","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/bjs.10843","article-title":"Mortality in patients with permanent hypoparathyroidism after total thyroidectomy","volume":"105","author":"Almquist","year":"2018","journal-title":"Br J Surg"},{"issue":"11","key":"2024031418592933600_jbmr4016-bib-0005","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024031418592933600_jbmr4016-bib-0006","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024031418592933600_jbmr4016-bib-0007","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2024031418592933600_jbmr4016-bib-0008","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"10","key":"2024031418592933600_jbmr4016-bib-0009","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024031418592933600_jbmr4016-bib-0010","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024031418592933600_jbmr4016-bib-0011","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024031418592933600_jbmr4016-bib-0012","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"issue":"6","key":"2024031418592933600_jbmr4016-bib-0013","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2024031418592933600_jbmr4016-bib-0014","author":"Shire-NPS Pharmaceuticals Inc. Highlights of prescribing information"},{"key":"2024031418592933600_jbmr4016-bib-0015","author":"Center for Drug Evaluation and Research","year":"2014"},{"issue":"3","key":"2024031418592933600_jbmr4016-bib-0016","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cpt.1200","article-title":"Use of a systems pharmacology model based approach toward dose optimization of parathyroid hormone therapy in Hypoparathyroidism","volume":"105","author":"Khurana","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2024031418592933600_jbmr4016-bib-0017","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1530\/EC-17-0203","article-title":"The rationale and design of TransCon growth hormone for the treatment of growth hormone deficiency","volume":"6","author":"Sprog\u00f8e","year":"2017","journal-title":"Endocr Connect"},{"issue":"Pt 2","key":"2024031418592933600_jbmr4016-bib-0018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/000456329803500203","article-title":"Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation","volume":"35","author":"Payne","year":"1998","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"2024031418592933600_jbmr4016-bib-0019","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-017-1479-y","article-title":"Quality of life in hypoparathyroidism","volume":"59","author":"Rejnmark","year":"2018","journal-title":"Endocrine"},{"issue":"4","key":"2024031418592933600_jbmr4016-bib-0020","first-page":"1525","article-title":"Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy","volume":"86","author":"Syed","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024031418592933600_jbmr4016-bib-0021","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024031418592933600_jbmr4016-bib-0022","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/jbmr.415","article-title":"A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover","volume":"26","author":"Horwitz","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024031418592933600_jbmr4016-bib-0023","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2024031418592933600_jbmr4016-bib-0024","volume-title":"Forteo highlights of prescribing information","author":"Eli Lilly and Co.","year":"2012"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.4016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/8\/1430\/55454339\/jbmr4016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/8\/1430\/55454339\/jbmr4016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T15:06:01Z","timestamp":1710428761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/35\/8\/1430\/7516517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,25]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4016","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4016\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4016\/v1\/review3","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,3,25]]},"assertion":[{"value":"2019-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}